June 2016 Blog Posts (15)

First Patient Recruited in New Trial with ONCOS-102 in Malignant Pleural Mesothelioma

This week Targovax, a clinical stage immuno-oncology company developing targeted immunotherapy treatments for cancer patients, announced that the first patient has been dosed in a phase Ib/II clinical trial evaluating ONCOS-102 for the treatment of malignant pleural mesothelioma (MPM), a rare type of cancer in the lining of the lung, in combination with pemetrexed and cisplatin.

ONCOS - 102 is a virus-based immunotherapy platform based on engineered…

Continue

Added by Editorial Team on June 30, 2016 at 4:30pm — No Comments

First Patient Dosed with Combination Trial of the BTK Inhibitor BGB-3111 with the PD-1 Antibody BGB-A317

Dosing of the first patient in a Phase I clinical trial of BGB-3111, a Bruton’s tyrosine kinase (BTK) inhibitor, in combination with BGB-A317, a PD-1 antibody, for the treatment of various B-cell malignancies was initiated earlier this week. This combination study of two internal drug candidates being developed by BeiGene, a clinical-stage biopharmaceutical company focused on developing molecularly targeted and immuno-oncology drugs for the treatment of cancer,  follows an ongoing study of…

Continue

Added by Editorial Team on June 29, 2016 at 8:30pm — No Comments

Persistent HPV Infection Raises Risk of Anal and Genital Cancers: Risk Can Persist More Than 20 Years After Infection

Women with a history of severe cervical intraepithelial neoplasia, a precancerous condition of the cervix that arises from infection with the human papillomavirus (HPV), had a long-term increased risk of developing anal, vulvar, and vaginal cancer. This is the conclusion of a study,  funded by the Unit of Virus, Lifestyle, and Genes at the Danish Cancer Society Research Center, published in Cancer Epidemiology,…

Continue

Added by Editorial Team on June 29, 2016 at 6:00pm — No Comments

Review of Multiple Studies Shows that Adherence to Cancer Prevention Guidelines may Reduce Risk

Following cancer prevention guidelines on diet and physical activity consistently reduced overall cancer incidence and mortality, as well as reducing risk of breast, endometrial, and colorectal cancers. Conclusions of the study, funded by a National Cancer Institute Cancer Center support grant, were published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the …

Continue

Added by Editorial Team on June 23, 2016 at 6:30pm — No Comments

Researchers find Potential to Render Breast Cancer Cells Less Able to Cope with Hypoxia

Researchers at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center, Princess Margaret Cancer Center, the University of Toronto, Harvard Medical School and Oxford University have identified a new signaling pathway that helps cancer cells cope with the lack of oxygen found inside tumors. These are the results of a study published in Nature Cell Biology on June 20, 2016.[1]

Oxygen is…

Continue

Added by Editorial Team on June 20, 2016 at 11:00am — No Comments

Life After Colon Cancer

Quality of life—it’s a term that gets thrown around a lot when people are sick. The phrase refers to how well you can live the life you want and how happy you are during it.  For patients with life-threatening conditions like colorectal cancer, it’s common to wonder, “What will I be like after my chemotherapy or radiation are over?” It’s a question that can be hard to answer and the truth is that life after cancer can look very different from patient to patient. How your life changes will…

Continue

Added by Editorial Team on June 16, 2016 at 8:00am — No Comments

Study Shows Neoadjuvant Chemotherapy may make Advanced Ovarian Cancers Responsive to Immunotherapy

Metastatic ovarian cancer patients treated with chemotherapy prior to surgery had altered immune cells in their tumors, and specific alterations identified suggest that immunotherapy given after chemotherapy may help in preventing the cancer from coming back.This is a conclusion of a study, funded by Swiss Cancer League, the European Research Council, Cancer Research U.K., and Barts and the London Charity, and published in…

Continue

Added by Editorial Team on June 15, 2016 at 8:00pm — No Comments

Imaging Technique may help Identify Residual Ovarian Tumors Left After Surgery and not Visible to Surgeons

A newly devised tumor-specific fluorescent agent and imaging system guided surgeons in real time to remove additional tumors in ovarian cancer patients that were not visible without fluorescence or could not be felt during surgery. That is an observation from a stud, study supported by On Target Laboratories, reported in Clinical Cancer…

Continue

Added by Editorial Team on June 15, 2016 at 7:30pm — No Comments

Seemingly Unimportant Distant Mutations may Drive Tumor Growth: Suggests Existing Therapies Could Work for Many Cancers

Examining databases of proteins’ 3-D shapes, scientists at Washington University School of Medicine in St. Louis have identified more than 850 DNA mutations that appear to be linked to cancer. The information may expand the number of cancer patients who can benefit from existing drugs. [1]

The study, published June 13 in Nature Genetics, detailed a list of the…

Continue

Added by Editorial Team on June 13, 2016 at 12:00pm — No Comments

Despite Lower Cost in Low-Income Countries, Cancer Drugs Retail Prices Vastly Different Between Countries and may be Less Affordable in Some

A pilot study revealed large differences in median retail prices for 23 cancer drugs in seven different countries, with the highest retail prices identified in the United States and the lowest in India and South Africa. Notably, after monthly drug price is expressed as a percentage of domestic product per capita at purchasing power parity (GDPcapPPP), cancer drugs appear to be less affordable in low-income countries, despite the lower retail prices. The study was featured…

Continue

Added by Editorial Team on June 7, 2016 at 2:00pm — No Comments

Rovalpituzumab Tesirine Shows Early Promise in the Treatment Small Cell Lung Cancer

Early findings from a first-in-human clinical trial showed that the antibody drug conjugate or ADC rovalpituzumab tesirine (Rova-T; SC16LD6.5) shows promising efficacy against recurrent small cell lung cancer (SCLC). The treatment, which combines a novel anti-DLL3 antibody with a powerful…

Continue

Added by Editorial Team on June 6, 2016 at 11:30pm — No Comments

Single-Agent NKTR-214 Produces a Large Increase in Tumor-Infiltrating Lymphocytes to Provide Durable Anti-Tumor Activity

New preclinical data for NKTR-214, an immuno-stimulatory CD-122 biased cytokine being developed by Nectar Therapeutics is currently being evaluated in cancer patients with solid tumors in a Phase I/II clinical trial being conducted at MD Anderson Cancer Center and Yale Cancer Center.[1]

The…

Continue

Added by Editorial Team on June 6, 2016 at 8:30pm — No Comments

ASG-15ME and Enfortumab Vedotin (ASG-22ME) Shows Anti-tumor Activity in Patients with Metastatic Urothelial Cancer

First-time clinical data for ASG-15ME and ASG-22ME (Enfortumab vedotin) were presented today at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting being held June 3-7, 2016 in Chicago, IL.

ASG-15ME and ASG-22ME are investigational…

Continue

Added by Editorial Team on June 6, 2016 at 12:00pm — No Comments

Atezolizumab Shrining Tumors in Patients with Previously Untreated Advanced Bladder Cancer

In a phase II study, IMvigor 210, atezolizumab (Tecentriq™; Genentech, a member of the Roche Group)shrank tumors (objective response rate, ORR) in 24% (n=28) of people with locally advanced or metastatic urothelial carcinoma (mUC) who have not received a prior treatment (first-line) and who were ineligible for cisplatin-based chemotherapy. Of those people who responded, 75% (n=21) continued to respond to treatment and the median duration of response (DOR) had not been reached at the…

Continue

Added by Editorial Team on June 5, 2016 at 8:30pm — No Comments

Fat Storage may make Cancer Cells more Aggressive

It has been established that not all cancer cells are equally aggressive – most can be neutralised with radiation and chemotherapy. Researchers at Lund University in Sweden have now discovered that some cancer cells can accumulate fat droplets, which appear to make them more aggressive and increase their ability to spread. [1]

The interior of a cancer tumour is a hostile environment with oxygen deficiency, low pH levels and lack of nutrients. The cells that survive in this…

Continue

Added by Editorial Team on June 3, 2016 at 9:00pm — No Comments

Monthly Archives

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2005

2004

2001

Register for free to view all the Onco'Zine - The International Oncology Network content:

ADVERTISEMENT/MEDIA PARTNER

Onco'Zine is present here

Bookmark / Share

CONNECT WITH US AND

JOIN THE CONVERSATION


© 2017   Created by Peter Hofland, PhD.   Powered by

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+